Active Pharmaceutical Ingredient (API)
Imatinib Mesylate
Tyrosine Kinase Inhibitor (TKI)
A revolutionary drug used to treat certain cancers, primarily Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST). It is a Tyrosine Kinase Inhibitor (TKI) that selectively blocks the activity of the abnormal $\text{BCR-ABL}$ protein, which drives CML cell proliferation. It is a cornerstone of targeted cancer therapy.
Technical Profile
- Reference Code
- IMA211
- CAS Number
- 220127-57-1
- Chemical Class
- N/A
- Therapeutic Class
- N/A
Verified Brands
Medicines containing Imatinib Mesylate as an active ingredient.
| Brand Name | Manufacturer | Formulation | MRP | |
|---|---|---|---|---|
| Imtinib 400 H | Brawn Laboratories Ltd | Tablet (400 mg) | ₹2,150.00 | View Details |
| Kwalitinib 100 H | Kwality Pharmaceuticals Ltd | Capsule (100 mg) | ₹850.00 | View Details |
| Kwalitinib 400 H | Kwality Pharmaceuticals Ltd | Tablet (400 mg) | ₹2,450.00 | View Details |
| Imatib 400 H | Cipla Limited | Tablet (400 mg) | ₹600.00 | View Details |
| Matnib 400 H | Getwell Oncology | Tablet (400 mg) | ₹2,100.00 | View Details |